Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner,Trinayan Kashyap,Jana L Dawson, Juan A Gomez, Alexis Bauer,Steven Grant,Yun Dai,Kenneth H. Shain,Mark B Meads,Yosef Landesman,Daniel M Sullivan

Blood（2016）

引用 0|浏览0

暂无评分

摘要

Introduction: Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired-resistance in MM.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要